Autonomix medical, inc. granted u.s. patent covering sensing data collection and processing with company's proprietary catheter-based technology

Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications  proprietary sensing and ablation technology has demonstrated potential to more precisely target and eliminate overactive nerves, improving response rates and enhancing patient outcomes across multiple indications the woodlands, tx, march 20, 2025 (globe newswire) -- autonomix medical, inc. (nasdaq: amix) (“autonomix” or the “company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that the united states patent and trademark office (uspto) has issued u.s. patent 12,217,863 (‘863 patent) titled, medical devices with circuitry for capturing and processing physiological signals. the issued ‘863 patent gives autonomix protection of proprietary technology used to collect and process sensing data for real-time physiological monitoring with broad application use that includes, e.g.
AMIX Ratings Summary
AMIX Quant Ranking